BAM
RETA

Belpointe Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Belpointe Asset Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-311
Closed -$28.3K – 3653
2023
Q1 		$28.3K Buy
311
+219
+238% +$12.9K ﹤0.01% 2093
2022
Q4 		$3.5K Buy
+92
New +$3.17K ﹤0.01% 3058

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belpointe Asset Management's RETA Position: Q2 2023 in Review

Belpointe Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 311 shares — an estimated $28.3K sold.

Belpointe Asset Management first reported a position in RETA in Q4 2022 and held it in 2 quarters. The position peaked at $28.3K in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Belpointe Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 311 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $28.3K.
  • Belpointe Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $28.3K in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.